Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pöllmann, W.
Right arrow Articles by Straube, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pöllmann, W.
Right arrow Articles by Straube, A.
Related Collections
Right arrow All Headache
Right arrow All Clinical trials
Right arrow Multiple sclerosis

Neurology 2002;59:636-639
© 2002 American Academy of Neurology
Brief Communications

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS

W. Pöllmann, MD, L. -P. Erasmus, PhD, W. Feneberg, MD, F. Then Bergh, MD and A. Straube, MD

From the Marianne–Strauss–Klinik (Drs. Pöllmann, Erasmus, and Feneberg), Berg; the Department of Neuroimmunology (Dr. Then Bergh), University of Munich; and the Department of Neurology (Dr. Straube), University of Munich, Klinikum Grosshadern, Germany.

Address correspondence and reprint requests to Dr. Walter Pöllmann, Marianne–Strauss–Klinik, Milchberg 21, Germany, D-82335 Berg; e-mail: WPoellmannMue{at}aol.com

Type and frequency of headaches during immunomodulatory therapy in MS were determined in 167 consecutive patients. In a prospective group of 65 patients beginning interferon beta therapy, headache frequency and duration increased in 18% of all and in 35% of patients with pre-existing headache by more than 50% during the first 6 months. In two retrospective groups, increased headache frequency was reported by 34% of 53 patients on interferon beta, but by only 6% of 49 patients during at least 6 months of glatiramer acetate therapy.




This article has been cited by other articles:


Home page
 Mult SclerHome page
F Martinelli Boneschi, B Colombo, P Annovazzi, V Martinelli, L Bernasconi, C Solaro, and G Comi
Lifetime and actual prevalence of pain and headache in multiple sclerosis
Multiple Sclerosis, May 1, 2008; 14(4): 514 - 521.
[Abstract] [PDF]

Home page
 Mult SclerHome page
L L. Mantia, D D'Amico, A Rigamonti, N Mascoli, G Bussone, and C Milanese
Interferon treatment may trigger primary headaches in multiple sclerosis patients
Multiple Sclerosis, August 1, 2006; 12(4): 476 - 480.
[Abstract] [PDF]

Home page
 NeurologyHome page
W. Pollmann, L.-P. Erasmus, W. Feneberg, and A. Straube
The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS
Neurology, January 24, 2006; 66(2): 275 - 277.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Langer-Gould, H. H. Moses, and T. J. Murray
Strategies for managing the side effects of treatments for multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S35 - S41.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.